Participants aged ≥18 undergoing hemodialysis were recruited and randomly assigned to one of three study groups.~Experimental Group : The participants received the first dose of BBIBP-Corv and IIV4 simultaneously on Day 0, and received the second dose of BBIBP-Corv and PPV23 simultaneously on Day 28.~Control Group 1: The participants received two doses of BBIBP-Corv on Day 0 and Day 28, respectively.~Control Group 2 : The participants received one doses of IIV4 on Day 0 and received one doses of PPV23 on Day 28.~Three blood samples were collected on days 0, 28 and 56 to test humoral immunity, and three blood samples were collected on days 0, 42 and 56 to test cellular immunity to SARS-CoV-2.~Any local or systemic adverse events after vaccination will be recorded.
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.